Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
During the study, participants completed a survey every evening pertaining to migraine occurrence and possible migraine predictors on an iPhone specific application.
Occipital nerve stimulation has been proposed to treat refractory chronic cluster headache but this study aimed to evaluate ONS long-term efficacy in rCCH.
The HER-MES study included 777 adult patients suffering from at least 4 migraine days/month and who were naïve to, not suitable for, or had previously failed up to 3 prophylactic treatments.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
This post hoc analysis assessed the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and QOL in adults with chronic migraine.
Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.
